Upcoming regulatory changes surrounding the use of perfluoroalkyl and polyfluoroalkyl substances (PFAS) have been making headlines across the globe. As the United States and European Union continue to move toward banning and limiting the use of PFAS products, the pharmaceutical industry, much like others, must address the mounting risks related to this family of chemicals.